Synergistic Triple Modality PET/SPECT/CT Reconstruction for Early Detection and Treatment of Cancer

1)简要描述研究背景及潜在影响pet /CT及SPECT/CT成像广泛应用于癌症、炎症、感染、钙化的诊断及治疗效果的评价。常规进行SPECT/CT和PET/CT扫描，并分别重建数据。medio发明了第一款三模扫描器AnyScan。该设备不仅将通过减少诊断/治疗所需的单独扫描次数来改善患者体验，而且将提供使用几乎相同的患者设置和示踪剂摄取/患者生理的小时间变化的不同模式进行成像的机会。这种并发的多模态成像将允许使用来自不同模态的信息将图像数据协同重建到同一图像中。输入数据量的增加将有助于图像重建的改进。同样的想法也可以应用于非同时拍摄的图像，以便产生比单独重建时包含更多临床数据和更好分辨率的组合图像。提高重建图像质量的影响将有助于疾病的早期发现和评估，以及提高监测治疗治疗的能力。这将改善患者的预后。由于图像重建时间的减少而导致的临床工作流程的任何改进都意味着可以提高患者的吞吐量，从而节省中心的时间和金钱。2)目的和目标本项目旨在利用三模态扫描仪同时获得的PET/SPECT/CT扫描信息，以及在不同时间点获得的双模态扫描仪。该项目将利用这些多种模式的数据开发和测试重建方法，以改善临床扫描产生的图像。使用多模态能够提高成像的准确性和精度，并减少重建所需的时间。这将导致更准确的诊断和治疗跟踪，改善患者的结果，以及改善临床环境中的工作流程。重建方法的适用性将通过使用NPL的实验室设备（包含三模成像器）来测试，使用含有不同浓度，类型和分布的放射性示踪剂的患者幻影。3)研究方法的新颖性协同重建将首次充分利用PET/SPECT/CT图像数据。该研究将使用PET/SPECT/CT从其类型的第一三重模态成像仪获得。所开发的重建方法将有助于提高这种新设备的诊断能力，甚至提高从非并发扫描中获得的信息的数量和质量，以前这些信息必须单独重建，然后将图像融合。4)与EPSRC的战略和研究领域保持一致。该项目将通过新颖的计算科学优化治疗，改善癌症等疾病的诊断和治疗。5)任何涉及medio LTD .国家物理实验室的公司或合作者

1) Brief description of the context of the research including potential impactPET/CT & SPECT/CT imaging is used widely in the diagnosis of cancer, inflammation, infection, calcification and for the evaluation of treatment efficacy. SPECT/CT & PET/CT scans are routinely performed, and the data reconstructed, separately. Mediso has created the first triple-modality scanner, AnyScan. This device will not only improve patient experience by reducing the number of separate scans required for diagnosis/treatment but will provide the opportunity to image using different modalities with near-identical patient setup and small temporal variations in tracer uptake / patient physiology.This concurrent multi-modality imaging will allow image data to be synergistically reconstructed using information from different modalities into the same image. The increased amount of input data will allow for improvements in image reconstruction. The same thinking could be applied to images taken non-concurrently in order to produce combined images containing more clinical data and better resolution than when reconstructed separately.The impact of improving the reconstructed image quality will be to help the early detection and evaluation of disease, as well as improve the ability to monitor treatment therapy. This will result in improved patient outcome. Any improvements in clinical workflow resulting from reductions in image reconstruction time will mean that patient throughput can be improved, saving centres time and money. 2) Aims and ObjectivesThis project aims to use information from PET/SPECT/CT scans obtained simultaneously using a triple modality scanner, as well as on dual-modality scanners acquired at different time points. The project will develop and test reconstruction methods using the data from these multiple modalities in order to improve the images produced from clinical scans. Using multi-modalities has the capacity to improve the accuracy and precision of imaging, as well as reduce the time needed for reconstruction. This will result in more accurate diagnosis and tracking of therapy, improving patient outcome, as well as improve workflow in a clinical environment.The suitability of the reconstruction methods will be tested by making use of the NPL's lab facilities (which contain a triple-modality imager) using patient phantoms containing varying concentrations, types and distributions of radiotracers.3) Novelty of Research MethodologySynergistic reconstruction will fully utilise data from PET/SPECT/CT images for the first time. The research will use PET/SPECT/CT obtained from the first triple modality imager of its kind. The reconstruction methods developed will help to improve the theragnostic capabilities of this new device and even improve the amount and quality of information obtained from non-concurrent scans, which would previously have to have been reconstructed separately and then the images fused.4) Alignment to EPSRC's strategies and research areasThis project will optimise treatment through novel computational science, improving the diagnosis and treatment of diseases such as cancer.5) Any companies or collaborators involvedNational Physics Laboratory, Mediso LTD